100%
Skip to main content
Platform
GovTribe AI
AI-powered insights to accelerate your government contracting workflow.
MCP Server
Connect GovTribe to your AI tools.
Beacon
Find and connect with key government decision-makers.
Profiles
Federal Agencies
Federal Contract Vehicles
Federal Grant Programs
Major Defense Acquisition Programs
NAICS Categories
PSC Categories
States
Jurisdictions
NIGP Categories
UNSPSC Categories
Vendors
Enrichment By Clearbit
Reports
New Entrants
Funding Analysis
Vehicle Analysis
Groups
Capture
Pipelines
Pursuits
Alerts
Teaming
Data
Awards
Forecasts
Federal Opportunities
State & Local Opportunities
Files
Prime and Subcontractors
Activity
Search
Exports
Solutions
Use Case
Opportunity Identification
Capture Management
Competitive Intelligence
Teaming & Partner Identification
Proposal Management
Strategic Leadership
Go-to-Market Strategy
Industry
Federal Contractors
State & Local Contractors
Grant Seekers
Government Agencies
Research & Consulting
Pricing
More
About Us
Features
Get A Demo
Sign Up
Blog
User Guide
Data Model
GovTribe for Agents
Login
Contact sales
Try for free
Login
Contact sales
Try for free
All Federal Grant Awards
Project Grant R44HL131338
Award Date
8/15/16
Completion Date
3/31/24
Dollars Obligated
$1.3M
Overview
Activity
10
Transactions
10
Subawards
Similar Awards
Federal Agency
National Heart Lung and Blood Institute
Awardee
Ension Inc. (Y4P6UDJLXLN3)
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Butler, PA, USA
Update #1
Update #2
SYSTEM AND COMPREHENSIVE APPROACH FOR BLOOD COMPATIBILITY OF MEDICAL DEVICES AND BIOMATERIAL
Posted 4/23/19
5
1
2
Mod #
Description
ReasonForModification
Federal Obligation
Date
Not listed
SYSTEM AND COMPREHENSIVE APPROACH FOR BLOOD COMPATIBILITY OF MEDICAL DEVICES AND BIOMATERIAL - ABSTRACT -TO DATE, BLOOD COMPATIBILITY TESTING OF BIOMATERIALS AND MEDICAL DEVICES HAS NOT LED TO A CONSENSUS ON WHAT MATERIALS ARE NON-THROMBOGENIC NOR HAS IT ADVANCED UNDERSTANDING OF WHAT AND HOW VARIABLES AND RESPONSES CAN BE MEASURED IN VITRO TO BEGIN TO PREDICT IN VIVO PERFORMANCE. WHILE ISO 10993-4 IDENTIFIES FIVE CATEGORIES OF RESPONSES THAT SHOULD BE CONSIDERED (THROMBOSIS, COAGULATION, PLATELETS, LEUKOCYTE ACTIVATION, AND COMPLEMENT), THE SCIENTIFIC AND REGULATORY COMMUNITIES CONTINUE TO FOCUS ON COAGULATION AND PLATELETS. THE OTHER ISO CATEGORIES DEALING WITH INFLAMMATION ARE TYPICALLY DEALT WITH EARLY AND SEPARATELY AS PART OF BIOMATERIAL DEVELOPMENT. THIS CURRENT APPROACH ALL BUT GUARANTEES MISSING INTERACTIONS OF COAGULATION AND INFLAMMATION NECESSARY TO PREDICT IN VIVO PERFORMANCE. CURRENT TESTING METHODOLOGIES ALSO FAIL TO EVALUATE THE CATEGORICAL RESPONSES UNDER PHYSIOLOGICAL LIMITS OF THE KEY VIRCHOW VARIABLES OF BLOOD FLOW, CONDITION OF THE BLOOD (E.G., COAGULOPATHIES), AND THE INFLUENCE OF THE BLOOD CONTACTING SURFACE. THESE UNCERTAINTIES AND THE CURRENT COST OF COMPREHENSIVE TESTING STIFLE DEVELOPMENT OF NEW MATERIALS OR SURFACE COATINGS. IN FACT, THE FDA HAS REPEATEDLY ACKNOWLEDGED THESE SHORTCOMINGS AND ENCOURAGED DEVELOPMENT OF NEW TEST METHODS AND FORMULATED THE MEDICAL DEVICE DEVELOPMENT TOOL (MDDT) PROGRAM TO ADDRESS THIS MATTER. ENSION PROPOSES DEVELOPMENT OF A SYSTEM (ENSION TRIAD SYSTEM OR ETS) TO PROVIDE EFFECTIVE POSITIVE AND NEGATIVE CONTROL RANGES FOR EACH OF THE VIRCHOW VARIABLES. ETS WILL ENABLE DESIGNED EXPERIMENTS CAPABLE OF GENERATING QUANTITATIVE ANALYSIS OF VARIANCE AND IDENTIFY CONDITIONS FOR OPTIMAL PERFORMANCE IN ALL FIVE ISO CATEGORIES. ENSION DEVELOPED AND DEMONSTRATED THE FEASIBILITY OF THE ETS SYSTEM IN OUR PHASE I ACTIVITIES DEMONSTRATING STATISTICALLY SIGNIFICANT CATEGORICAL RESPONSES THAT IDENTIFY KNOWN CLINICAL MEDIATORS NOT REVEALED IN CURRENT TESTING PROTOCOLS. THIS PHASE II PROJECT REPRESENTS THE MAIN RESEARCH AND DEVELOPMENT FOR ETS WITH THE END- GOAL TO SUBMIT TO FDA'S MDDT PROGRAM FOR SYSTEM QUALIFICATION. IN SPECIFIC AIM 1 WE WILL REFINE THE PHASE I ETS DESIGN FOR MANUFACTURABILITY, CONDUCT GMP-BASED FABRICATION OF ETS SYSTEMS IN SUFFICIENT QUANTITIES TO SUPPORT THE NEEDS OF SPECIFIC AIM 2 AND SPECIFIC AIM 3. IN SPECIFIC AIM 2, ETS SYSTEMS WITHOUT TEST ARTICLES WILL BE USED TO CHARACTERIZE THE CONFIDENCE INTERVAL OF THE RESPONSES OF THE FIVE ISO 10993 CATEGORIES AS A FUNCTION OF THE KEY VIRCHOW INDEPENDENT VARIABLES. FINALLY, IN SPECIFIC AIM 3 ETS SYSTEMS WILL BE EVALUATED IN HUMAN BLOOD USING PROTOTYPE CATHETERS AS TEST ARTICLES AND DATA WILL BE COMPARED WITH CURRENT ISO CATEGORIAL BLOOD COMPATIBILITY EVALUATIONS.
$0
7/23/24
Not listed
SYSTEM AND COMPREHENSIVE APPROACH FOR BLOOD COMPATIBILITY OF MEDICAL DEVICES AND BIOMATERIAL - ABSTRACT -TO DATE, BLOOD COMPATIBILITY TESTING OF BIOMATERIALS AND MEDICAL DEVICES HAS NOT LED TO A CONSENSUS ON WHAT MATERIALS ARE NON-THROMBOGENIC NOR HAS IT ADVANCED UNDERSTANDING OF WHAT AND HOW VARIABLES AND RESPONSES CAN BE MEASURED IN VITRO TO BEGIN TO PREDICT IN VIVO PERFORMANCE. WHILE ISO 10993-4 IDENTIFIES FIVE CATEGORIES OF RESPONSES THAT SHOULD BE CONSIDERED (THROMBOSIS, COAGULATION, PLATELETS, LEUKOCYTE ACTIVATION, AND COMPLEMENT), THE SCIENTIFIC AND REGULATORY COMMUNITIES CONTINUE TO FOCUS ON COAGULATION AND PLATELETS. THE OTHER ISO CATEGORIES DEALING WITH INFLAMMATION ARE TYPICALLY DEALT WITH EARLY AND SEPARATELY AS PART OF BIOMATERIAL DEVELOPMENT. THIS CURRENT APPROACH ALL BUT GUARANTEES MISSING INTERACTIONS OF COAGULATION AND INFLAMMATION NECESSARY TO PREDICT IN VIVO PERFORMANCE. CURRENT TESTING METHODOLOGIES ALSO FAIL TO EVALUATE THE CATEGORICAL RESPONSES UNDER PHYSIOLOGICAL LIMITS OF THE KEY VIRCHOW VARIABLES OF BLOOD FLOW, CONDITION OF THE BLOOD (E.G., COAGULOPATHIES), AND THE INFLUENCE OF THE BLOOD CONTACTING SURFACE. THESE UNCERTAINTIES AND THE CURRENT COST OF COMPREHENSIVE TESTING STIFLE DEVELOPMENT OF NEW MATERIALS OR SURFACE COATINGS. IN FACT, THE FDA HAS REPEATEDLY ACKNOWLEDGED THESE SHORTCOMINGS AND ENCOURAGED DEVELOPMENT OF NEW TEST METHODS AND FORMULATED THE MEDICAL DEVICE DEVELOPMENT TOOL (MDDT) PROGRAM TO ADDRESS THIS MATTER. ENSION PROPOSES DEVELOPMENT OF A SYSTEM (ENSION TRIAD SYSTEM OR ETS) TO PROVIDE EFFECTIVE POSITIVE AND NEGATIVE CONTROL RANGES FOR EACH OF THE VIRCHOW VARIABLES. ETS WILL ENABLE DESIGNED EXPERIMENTS CAPABLE OF GENERATING QUANTITATIVE ANALYSIS OF VARIANCE AND IDENTIFY CONDITIONS FOR OPTIMAL PERFORMANCE IN ALL FIVE ISO CATEGORIES. ENSION DEVELOPED AND DEMONSTRATED THE FEASIBILITY OF THE ETS SYSTEM IN OUR PHASE I ACTIVITIES DEMONSTRATING STATISTICALLY SIGNIFICANT CATEGORICAL RESPONSES THAT IDENTIFY KNOWN CLINICAL MEDIATORS NOT REVEALED IN CURRENT TESTING PROTOCOLS. THIS PHASE II PROJECT REPRESENTS THE MAIN RESEARCH AND DEVELOPMENT FOR ETS WITH THE END- GOAL TO SUBMIT TO FDA'S MDDT PROGRAM FOR SYSTEM QUALIFICATION. IN SPECIFIC AIM 1 WE WILL REFINE THE PHASE I ETS DESIGN FOR MANUFACTURABILITY, CONDUCT GMP-BASED FABRICATION OF ETS SYSTEMS IN SUFFICIENT QUANTITIES TO SUPPORT THE NEEDS OF SPECIFIC AIM 2 AND SPECIFIC AIM 3. IN SPECIFIC AIM 2, ETS SYSTEMS WITHOUT TEST ARTICLES WILL BE USED TO CHARACTERIZE THE CONFIDENCE INTERVAL OF THE RESPONSES OF THE FIVE ISO 10993 CATEGORIES AS A FUNCTION OF THE KEY VIRCHOW INDEPENDENT VARIABLES. FINALLY, IN SPECIFIC AIM 3 ETS SYSTEMS WILL BE EVALUATED IN HUMAN BLOOD USING PROTOTYPE CATHETERS AS TEST ARTICLES AND DATA WILL BE COMPARED WITH CURRENT ISO CATEGORIAL BLOOD COMPATIBILITY EVALUATIONS.
$0
7/1/23
Not listed
SYSTEM AND COMPREHENSIVE APPROACH FOR BLOOD COMPATIBILITY OF MEDICAL DEVICES AND BIOMATERIAL - ABSTRACT -TO DATE, BLOOD COMPATIBILITY TESTING OF BIOMATERIALS AND MEDICAL DEVICES HAS NOT LED TO A CONSENSUS ON WHAT MATERIALS ARE NON-THROMBOGENIC NOR HAS IT ADVANCED UNDERSTANDING OF WHAT AND HOW VARIABLES AND RESPONSES CAN BE MEASURED IN VITRO TO BEGIN TO PREDICT IN VIVO PERFORMANCE. WHILE ISO 10993-4 IDENTIFIES FIVE CATEGORIES OF RESPONSES THAT SHOULD BE CONSIDERED (THROMBOSIS, COAGULATION, PLATELETS, LEUKOCYTE ACTIVATION, AND COMPLEMENT), THE SCIENTIFIC AND REGULATORY COMMUNITIES CONTINUE TO FOCUS ON COAGULATION AND PLATELETS. THE OTHER ISO CATEGORIES DEALING WITH INFLAMMATION ARE TYPICALLY DEALT WITH EARLY AND SEPARATELY AS PART OF BIOMATERIAL DEVELOPMENT. THIS CURRENT APPROACH ALL BUT GUARANTEES MISSING INTERACTIONS OF COAGULATION AND INFLAMMATION NECESSARY TO PREDICT IN VIVO PERFORMANCE. CURRENT TESTING METHODOLOGIES ALSO FAIL TO EVALUATE THE CATEGORICAL RESPONSES UNDER PHYSIOLOGICAL LIMITS OF THE KEY VIRCHOW VARIABLES OF BLOOD FLOW, CONDITION OF THE BLOOD (E.G., COAGULOPATHIES), AND THE INFLUENCE OF THE BLOOD CONTACTING SURFACE. THESE UNCERTAINTIES AND THE CURRENT COST OF COMPREHENSIVE TESTING STIFLE DEVELOPMENT OF NEW MATERIALS OR SURFACE COATINGS. IN FACT, THE FDA HAS REPEATEDLY ACKNOWLEDGED THESE SHORTCOMINGS AND ENCOURAGED DEVELOPMENT OF NEW TEST METHODS AND FORMULATED THE MEDICAL DEVICE DEVELOPMENT TOOL (MDDT) PROGRAM TO ADDRESS THIS MATTER. ENSION PROPOSES DEVELOPMENT OF A SYSTEM (ENSION TRIAD SYSTEM OR ETS) TO PROVIDE EFFECTIVE POSITIVE AND NEGATIVE CONTROL RANGES FOR EACH OF THE VIRCHOW VARIABLES. ETS WILL ENABLE DESIGNED EXPERIMENTS CAPABLE OF GENERATING QUANTITATIVE ANALYSIS OF VARIANCE AND IDENTIFY CONDITIONS FOR OPTIMAL PERFORMANCE IN ALL FIVE ISO CATEGORIES. ENSION DEVELOPED AND DEMONSTRATED THE FEASIBILITY OF THE ETS SYSTEM IN OUR PHASE I ACTIVITIES DEMONSTRATING STATISTICALLY SIGNIFICANT CATEGORICAL RESPONSES THAT IDENTIFY KNOWN CLINICAL MEDIATORS NOT REVEALED IN CURRENT TESTING PROTOCOLS. THIS PHASE II PROJECT REPRESENTS THE MAIN RESEARCH AND DEVELOPMENT FOR ETS WITH THE END- GOAL TO SUBMIT TO FDA'S MDDT PROGRAM FOR SYSTEM QUALIFICATION. IN SPECIFIC AIM 1 WE WILL REFINE THE PHASE I ETS DESIGN FOR MANUFACTURABILITY, CONDUCT GMP-BASED FABRICATION OF ETS SYSTEMS IN SUFFICIENT QUANTITIES TO SUPPORT THE NEEDS OF SPECIFIC AIM 2 AND SPECIFIC AIM 3. IN SPECIFIC AIM 2, ETS SYSTEMS WITHOUT TEST ARTICLES WILL BE USED TO CHARACTERIZE THE CONFIDENCE INTERVAL OF THE RESPONSES OF THE FIVE ISO 10993 CATEGORIES AS A FUNCTION OF THE KEY VIRCHOW INDEPENDENT VARIABLES. FINALLY, IN SPECIFIC AIM 3 ETS SYSTEMS WILL BE EVALUATED IN HUMAN BLOOD USING PROTOTYPE CATHETERS AS TEST ARTICLES AND DATA WILL BE COMPARED WITH CURRENT ISO CATEGORIAL BLOOD COMPATIBILITY EVALUATIONS.
$0
3/9/22
Not listed
SYSTEM AND COMPREHENSIVE APPROACH FOR BLOOD COMPATIBILITY OF MEDICAL DEVICES AND BIOMATERIAL - ABSTRACT -TO DATE, BLOOD COMPATIBILITY TESTING OF BIOMATERIALS AND MEDICAL DEVICES HAS NOT LED TO A CONSENSUS ON WHAT MATERIALS ARE NON-THROMBOGENIC NOR HAS IT ADVANCED UNDERSTANDING OF WHAT AND HOW VARIABLES AND RESPONSES CAN BE MEASURED IN VITRO TO BEGIN TO PREDICT IN VIVO PERFORMANCE. WHILE ISO 10993-4 IDENTIFIES FIVE CATEGORIES OF RESPONSES THAT SHOULD BE CONSIDERED (THROMBOSIS, COAGULATION, PLATELETS, LEUKOCYTE ACTIVATION, AND COMPLEMENT), THE SCIENTIFIC AND REGULATORY COMMUNITIES CONTINUE TO FOCUS ON COAGULATION AND PLATELETS. THE OTHER ISO CATEGORIES DEALING WITH INFLAMMATION ARE TYPICALLY DEALT WITH EARLY AND SEPARATELY AS PART OF BIOMATERIAL DEVELOPMENT. THIS CURRENT APPROACH ALL BUT GUARANTEES MISSING INTERACTIONS OF COAGULATION AND INFLAMMATION NECESSARY TO PREDICT IN VIVO PERFORMANCE. CURRENT TESTING METHODOLOGIES ALSO FAIL TO EVALUATE THE CATEGORICAL RESPONSES UNDER PHYSIOLOGICAL LIMITS OF THE KEY VIRCHOW VARIABLES OF BLOOD FLOW, CONDITION OF THE BLOOD (E.G., COAGULOPATHIES), AND THE INFLUENCE OF THE BLOOD CONTACTING SURFACE. THESE UNCERTAINTIES AND THE CURRENT COST OF COMPREHENSIVE TESTING STIFLE DEVELOPMENT OF NEW MATERIALS OR SURFACE COATINGS. IN FACT, THE FDA HAS REPEATEDLY ACKNOWLEDGED THESE SHORTCOMINGS AND ENCOURAGED DEVELOPMENT OF NEW TEST METHODS AND FORMULATED THE MEDICAL DEVICE DEVELOPMENT TOOL (MDDT) PROGRAM TO ADDRESS THIS MATTER. ENSION PROPOSES DEVELOPMENT OF A SYSTEM (ENSION TRIAD SYSTEM OR ETS) TO PROVIDE EFFECTIVE POSITIVE AND NEGATIVE CONTROL RANGES FOR EACH OF THE VIRCHOW VARIABLES. ETS WILL ENABLE DESIGNED EXPERIMENTS CAPABLE OF GENERATING QUANTITATIVE ANALYSIS OF VARIANCE AND IDENTIFY CONDITIONS FOR OPTIMAL PERFORMANCE IN ALL FIVE ISO CATEGORIES. ENSION DEVELOPED AND DEMONSTRATED THE FEASIBILITY OF THE ETS SYSTEM IN OUR PHASE I ACTIVITIES DEMONSTRATING STATISTICALLY SIGNIFICANT CATEGORICAL RESPONSES THAT IDENTIFY KNOWN CLINICAL MEDIATORS NOT REVEALED IN CURRENT TESTING PROTOCOLS. THIS PHASE II PROJECT REPRESENTS THE MAIN RESEARCH AND DEVELOPMENT FOR ETS WITH THE END- GOAL TO SUBMIT TO FDA'S MDDT PROGRAM FOR SYSTEM QUALIFICATION. IN SPECIFIC AIM 1 WE WILL REFINE THE PHASE I ETS DESIGN FOR MANUFACTURABILITY, CONDUCT GMP-BASED FABRICATION OF ETS SYSTEMS IN SUFFICIENT QUANTITIES TO SUPPORT THE NEEDS OF SPECIFIC AIM 2 AND SPECIFIC AIM 3. IN SPECIFIC AIM 2, ETS SYSTEMS WITHOUT TEST ARTICLES WILL BE USED TO CHARACTERIZE THE CONFIDENCE INTERVAL OF THE RESPONSES OF THE FIVE ISO 10993 CATEGORIES AS A FUNCTION OF THE KEY VIRCHOW INDEPENDENT VARIABLES. FINALLY, IN SPECIFIC AIM 3 ETS SYSTEMS WILL BE EVALUATED IN HUMAN BLOOD USING PROTOTYPE CATHETERS AS TEST ARTICLES AND DATA WILL BE COMPARED WITH CURRENT ISO CATEGORIAL BLOOD COMPATIBILITY EVALUATIONS.
$0
3/9/22
Not listed
SYSTEM AND COMPREHENSIVE APPROACH FOR BLOOD COMPATIBILITY OF MEDICAL DEVICES AND BIOMATERIAL - ABSTRACT -TO DATE, BLOOD COMPATIBILITY TESTING OF BIOMATERIALS AND MEDICAL DEVICES HAS NOT LED TO A CONSENSUS ON WHAT MATERIALS ARE NON-THROMBOGENIC NOR HAS IT ADVANCED UNDERSTANDING OF WHAT AND HOW VARIABLES AND RESPONSES CAN BE MEASURED IN VITRO TO BEGIN TO PREDICT IN VIVO PERFORMANCE. WHILE ISO 10993-4 IDENTIFIES FIVE CATEGORIES OF RESPONSES THAT SHOULD BE CONSIDERED (THROMBOSIS, COAGULATION, PLATELETS, LEUKOCYTE ACTIVATION, AND COMPLEMENT), THE SCIENTIFIC AND REGULATORY COMMUNITIES CONTINUE TO FOCUS ON COAGULATION AND PLATELETS. THE OTHER ISO CATEGORIES DEALING WITH INFLAMMATION ARE TYPICALLY DEALT WITH EARLY AND SEPARATELY AS PART OF BIOMATERIAL DEVELOPMENT. THIS CURRENT APPROACH ALL BUT GUARANTEES MISSING INTERACTIONS OF COAGULATION AND INFLAMMATION NECESSARY TO PREDICT IN VIVO PERFORMANCE. CURRENT TESTING METHODOLOGIES ALSO FAIL TO EVALUATE THE CATEGORICAL RESPONSES UNDER PHYSIOLOGICAL LIMITS OF THE KEY VIRCHOW VARIABLES OF BLOOD FLOW, CONDITION OF THE BLOOD (E.G., COAGULOPATHIES), AND THE INFLUENCE OF THE BLOOD CONTACTING SURFACE. THESE UNCERTAINTIES AND THE CURRENT COST OF COMPREHENSIVE TESTING STIFLE DEVELOPMENT OF NEW MATERIALS OR SURFACE COATINGS. IN FACT, THE FDA HAS REPEATEDLY ACKNOWLEDGED THESE SHORTCOMINGS AND ENCOURAGED DEVELOPMENT OF NEW TEST METHODS AND FORMULATED THE MEDICAL DEVICE DEVELOPMENT TOOL (MDDT) PROGRAM TO ADDRESS THIS MATTER. ENSION PROPOSES DEVELOPMENT OF A SYSTEM (ENSION TRIAD SYSTEM OR ETS) TO PROVIDE EFFECTIVE POSITIVE AND NEGATIVE CONTROL RANGES FOR EACH OF THE VIRCHOW VARIABLES. ETS WILL ENABLE DESIGNED EXPERIMENTS CAPABLE OF GENERATING QUANTITATIVE ANALYSIS OF VARIANCE AND IDENTIFY CONDITIONS FOR OPTIMAL PERFORMANCE IN ALL FIVE ISO CATEGORIES. ENSION DEVELOPED AND DEMONSTRATED THE FEASIBILITY OF THE ETS SYSTEM IN OUR PHASE I ACTIVITIES DEMONSTRATING STATISTICALLY SIGNIFICANT CATEGORICAL RESPONSES THAT IDENTIFY KNOWN CLINICAL MEDIATORS NOT REVEALED IN CURRENT TESTING PROTOCOLS. THIS PHASE II PROJECT REPRESENTS THE MAIN RESEARCH AND DEVELOPMENT FOR ETS WITH THE END- GOAL TO SUBMIT TO FDA'S MDDT PROGRAM FOR SYSTEM QUALIFICATION. IN SPECIFIC AIM 1 WE WILL REFINE THE PHASE I ETS DESIGN FOR MANUFACTURABILITY, CONDUCT GMP-BASED FABRICATION OF ETS SYSTEMS IN SUFFICIENT QUANTITIES TO SUPPORT THE NEEDS OF SPECIFIC AIM 2 AND SPECIFIC AIM 3. IN SPECIFIC AIM 2, ETS SYSTEMS WITHOUT TEST ARTICLES WILL BE USED TO CHARACTERIZE THE CONFIDENCE INTERVAL OF THE RESPONSES OF THE FIVE ISO 10993 CATEGORIES AS A FUNCTION OF THE KEY VIRCHOW INDEPENDENT VARIABLES. FINALLY, IN SPECIFIC AIM 3 ETS SYSTEMS WILL BE EVALUATED IN HUMAN BLOOD USING PROTOTYPE CATHETERS AS TEST ARTICLES AND DATA WILL BE COMPARED WITH CURRENT ISO CATEGORIAL BLOOD COMPATIBILITY EVALUATIONS.
$0
3/9/22